ATE204583T1 - Menschliche monocyte chemoattractantia proteine-1 (mcp) derivaten - Google Patents

Menschliche monocyte chemoattractantia proteine-1 (mcp) derivaten

Info

Publication number
ATE204583T1
ATE204583T1 AT95902480T AT95902480T ATE204583T1 AT E204583 T1 ATE204583 T1 AT E204583T1 AT 95902480 T AT95902480 T AT 95902480T AT 95902480 T AT95902480 T AT 95902480T AT E204583 T1 ATE204583 T1 AT E204583T1
Authority
AT
Austria
Prior art keywords
mcp
derivatives
substituted
monocyte chemoattractant
activity
Prior art date
Application number
AT95902480T
Other languages
English (en)
Inventor
Barrett Rollins
Yu Jun Zhang
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE204583T1 publication Critical patent/ATE204583T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95902480T 1993-11-12 1994-11-07 Menschliche monocyte chemoattractantia proteine-1 (mcp) derivaten ATE204583T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15230193A 1993-11-12 1993-11-12
PCT/US1994/012874 WO1995013295A1 (en) 1993-11-12 1994-11-07 Human monocyte chemoattractant protein-1 (mcp-1) derivatives

Publications (1)

Publication Number Publication Date
ATE204583T1 true ATE204583T1 (de) 2001-09-15

Family

ID=22542340

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95902480T ATE204583T1 (de) 1993-11-12 1994-11-07 Menschliche monocyte chemoattractantia proteine-1 (mcp) derivaten

Country Status (10)

Country Link
US (1) US5459128A (de)
EP (1) EP0725794B1 (de)
JP (3) JP4040083B2 (de)
AT (1) ATE204583T1 (de)
CA (1) CA2176217A1 (de)
DE (1) DE69428049T2 (de)
DK (1) DK0725794T3 (de)
ES (1) ES2162908T3 (de)
PT (1) PT725794E (de)
WO (1) WO1995013295A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869924B1 (en) * 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
IL92937A0 (en) * 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
JP4006021B2 (ja) 1993-06-08 2007-11-14 スミスクライン・ビーチャム・コーポレイション ケモカインの生物学的活性の強化法
US5663450A (en) * 1993-08-17 1997-09-02 Cv Therapeutics Macrophage lipid chemoattractant
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
JP3532570B2 (ja) * 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
US6100389A (en) * 1995-04-21 2000-08-08 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic protein
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US6491906B1 (en) 1995-06-01 2002-12-10 The Regents Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US7265083B2 (en) 1995-06-06 2007-09-04 The Regents Of The University Of Michigan Treatment of idiopathic pulmonary fibrosis using IP-10
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
AU708743B2 (en) * 1995-06-07 1999-08-12 Icos Corporation Macrophage derived chemokine and chemokine analogs
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US6320023B1 (en) 1995-06-07 2001-11-20 Icos Corporation Macrophage derived chemokine
US5688927A (en) * 1995-06-07 1997-11-18 Icos Corporation Macrophage derived chemokine
US6790947B1 (en) 1995-06-07 2004-09-14 Icos Corporation Polynucleotides encoding macrophage derived chemokine
US6042821A (en) * 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6274342B1 (en) 1996-09-18 2001-08-14 Center For Blood Research, Inc. Nucleic acid molecules encoding monocyte chemotactic protein 5 (MCP-5) molecules and uses therefor
US6673915B1 (en) 1996-09-30 2004-01-06 General Hospital Corporation Nucleic acid encoding monocyte chemotactic protein 4
WO1998014573A1 (en) * 1996-09-30 1998-04-09 The General Hospital Corporation Mcp-4 and mcp-5: novel chemokines
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6541208B1 (en) 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
JP4712975B2 (ja) * 1999-01-12 2011-06-29 ケンブリッジ エンタープライズ リミティド 炎症反応を阻害又は増強するための組成物及び方法
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7309693B2 (en) * 2000-05-26 2007-12-18 Kensuke Egashira Preventives and remedies for pulmonary hypertension
CN1469756A (zh) 2000-10-11 2004-01-21 江头健辅 治疗肝病的药物
US6902914B2 (en) * 2001-09-28 2005-06-07 Sigma-Aldrich, Co. Recombinant DNA processes using a dNTP mixture containing modified nucleotides
US20040116341A1 (en) * 2001-10-23 2004-06-17 Holtzman Michael J. Methods for ameliorating childhood infections
WO2004003195A1 (en) * 2002-06-28 2004-01-08 The Government Of The United States Of America,As Represented By The Secretary Of The Department Of Health And Human Services Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins
US7749714B2 (en) * 2003-03-12 2010-07-06 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating prostate cancer
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
WO2007021807A1 (en) * 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
WO2007148317A1 (en) * 2006-06-21 2007-12-27 Compugen Ltd. Mcp-1 splice variants and methods of using same
US9855370B2 (en) * 2008-01-08 2018-01-02 Yale University Compositions and methods for promoting patency of vascular grafts
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
WO2017100782A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patent specific tissue engineering vascular grafts

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168051A (en) * 1985-03-22 1992-12-01 Genentech, Inc. Nucleic acid encoding TGF-β its uses
IL92937A0 (en) * 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
US5212073A (en) * 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease

Also Published As

Publication number Publication date
JP2006225402A (ja) 2006-08-31
ES2162908T3 (es) 2002-01-16
US5459128A (en) 1995-10-17
EP0725794B1 (de) 2001-08-22
DE69428049T2 (de) 2002-04-18
CA2176217A1 (en) 1995-05-18
JP2008007520A (ja) 2008-01-17
JP4040083B2 (ja) 2008-01-30
DE69428049D1 (de) 2001-09-27
DK0725794T3 (da) 2001-12-10
WO1995013295A1 (en) 1995-05-18
JPH09505053A (ja) 1997-05-20
EP0725794A1 (de) 1996-08-14
PT725794E (pt) 2002-02-28

Similar Documents

Publication Publication Date Title
DE69428049D1 (de) Menschliche monocyte chemoattractantia proteine-1 (mcp) derivaten
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
NZ248377A (en) Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
DK0679092T3 (da) Cytokindæmpende midler
ATE245977T1 (de) Therapeutische substituierte guanidine
ATE406176T1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
GEP20012413B (en) Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
HUP0000492A1 (hu) N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
ATE278397T1 (de) Verwendung von cytoskelettinhibitoren zur vorbeugung der restenose
DE69637050D1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
DK0603301T3 (da) Farmaceutisk præparat indeholdende et urikosurikon og en excitatorisk-aminosyre-antagonist
DE69725860D1 (de) PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
SE9201628D0 (sv) Pharmaceutical composition
MY106067A (en) Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors.
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
TW369541B (en) Thrombin inhibitors
ATE359296T1 (de) Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
MX9709361A (es) Monomero de 4.4-ciclohexan-1-ols disubstituido y compuestos relacionados.
FR2658190B1 (fr) Esters d'aminoacides de l'hydroquinone, leur procede de preparation et compositions pharmaceutiques ou cosmetiques les contenant.
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
DK0811068T3 (da) Humane DNase I varianter
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
ATE139702T1 (de) Die freisetzung des histamin hemmenden faktors sowie diesen enthaltende präparate
MA23755A1 (fr) Cyclohexanes-1-ols disubstitues en 4,4 monomeres et composes similaires

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee